EXEL Latest Press Releases

-- February 24, 2026 --

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March Business Wire 4:05 PM

-- February 10, 2026 --

Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update Business Wire 4:05 PM

-- February 2, 2026 --

Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer Business Wire 8:00 AM

-- January 27, 2026 --

Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026 Business Wire 4:05 PM

-- January 11, 2026 --

Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 Business Wire 4:00 PM

-- January 7, 2026 --

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer Business Wire 8:00 AM

-- January 6, 2026 --

Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 Business Wire 4:05 PM

-- December 12, 2025 --

GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era Globe Newswire 10:31 AM

-- December 3, 2025 --

Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025 Business Wire 4:05 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software